Ascendis Pharma A (ASND) Accounts Payables (2012 - 2026)

Ascendis Pharma A has reported Accounts Payables for 15 years, with the latest figure at $92.0 million in Q1 2026.

• Quarterly Accounts Payables rose 3.67% year-over-year to $92.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $92.0 million (up 3.67% YoY) and the FY2025 annual result came in at $105.5 million, up 2.45% from the prior year.
• Accounts Payables retreated to $92.0 million in Q1 2026 per ASND's latest filing, from $105.5 million in the prior quarter.
• Over five years, Accounts Payables peaked at $141.1 million in Q1 2023 and troughed at $79.3 million in Q1 2022.
• A 5-year average of $102.2 million and a median of $102.7 million in 2024 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2023 and 2024: Accounts Payables soared 77.84% in 2023, then slumped 37.53% in 2024.
• Over 5 years, Accounts Payables stood at $103.1 million in 2022, then retreated by 1.29% to $101.7 million in 2023, then gained by 1.24% to $103.0 million in 2024, then advanced by 2.45% to $105.5 million in 2025, then decreased by 12.81% to $92.0 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $92.0 million, $105.5 million, and $91.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.